| golidocitinib (DZD4205) / Dizal Pharma |
NCT06511869: AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) |
|
|
| Active, not recruiting | 2 | 130 | RoW | AZD4205 | Dizal Pharmaceuticals | Peripheral T-cell Lymphoma | 03/25 | 03/26 | | |
NCT06511895: AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) |
|
|
| Recruiting | 2 | 150 | RoW | AZD4205 | Dizal Pharmaceuticals | Peripheral T Cell Lymphoma | 05/25 | 12/26 | | |
NCT06295432: A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) |
|
|
| Recruiting | 2 | 90 | RoW | DZD9008+AZD4205, Inapplicable | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 06/25 | 06/25 | | |
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL |
|
|
| Completed | 2 | 171 | US, RoW | AZD4205 | Dizal Pharmaceuticals | Relapsed or Refractory Peripheral T Cell Lymphoma | 10/23 | 02/24 | | |
JACKPOT33, NCT06198907: Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) |
|
|
| Not yet recruiting | 2 | 69 | RoW | Golidocitinib, Sintilimab, platinum doublet chemotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Dizal Pharmaceuticals | Non-Small-Cell Lung Cancer | 12/26 | 12/27 | | |
NCT06573138: Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL |
|
|
| Not yet recruiting | 2 | 18 | NA | Selinexor, anti-PD-1 antibody plus Golidocitinib | Ruijin Hospital | Lymphoma, Extranodal NK-T-Cell | 07/27 | 07/27 | | |
| Not yet recruiting | 2 | 47 | RoW | Golidocitinib, Benmelstobart | Sun Yat-sen University | Natural Killer T-cell Lymphoma | 12/26 | 12/28 | | |
| Not yet recruiting | 2 | 7 | NA | Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone), Golidocitinib | Ruijin Hospital | Enteropathy Associated T Cell Lymphoma | 05/26 | 12/27 | | |
NCT06630091: A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study |
|
|
| Not yet recruiting | 2 | 30 | US | Golidocitinib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone | M.D. Anderson Cancer Center | Peripheral T Cell Lymphoma | 07/27 | 07/29 | | |
| Recruiting | 2 | 45 | RoW | Golidocitinib, AZD4205, DZD4205, CHOP Regimen, Cyclophosphamide, doxorubicin, vincristine, prednisone | Henan Cancer Hospital | Peripheral T Cell Lymphoma | 07/25 | 07/26 | | |
NCT06739265: Golidocitinib Plus CHOP in Newly Diagnosed PTCL |
|
|
| Recruiting | 1/2 | 68 | RoW | Golidocitinib plus CHOP | Peking Union Medical College Hospital | Peripheral T-cell Lymphoma | 09/26 | 09/27 | | |
NCT06690671: A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC |
|
|
| Not yet recruiting | 1/2 | 30 | RoW | Golidocitinib in combination with anti-PD-1 | Shanghai Chest Hospital | Lung Cancer, Non-Small Cell | 06/25 | 06/26 | | |
NCT06757387: Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma |
|
|
| Not yet recruiting | 1/2 | 45 | NA | chidamide and golidocitinib | Peking University Cancer Hospital & Institute | Peripheral T-cell Lymphoma | 12/28 | 12/30 | | |
| sunvozertinib (DZD9008) / Dizal Pharma |
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) |
|
|
| Recruiting | 3 | 320 | Europe, Canada, US, RoW | DZD9008, Pemetrexed+carboplatin | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 02/26 | 10/27 | | |
NCT05712902: Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) |
|
|
| Active, not recruiting | 2 | 104 | RoW | Sunvozertinib, DZD9008 | Dizal Pharmaceuticals | Non-Small Cell Lung Cancer | 10/22 | 12/25 | | |
WU-KONG29, NCT06276283: DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation |
|
|
| Recruiting | 2 | 60 | RoW | DZD9008 plus Bevacizumab, Inapplicable | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 05/25 | 02/26 | | |
WUKONG-9, NCT06182761: A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 45 | NA | Sunvozertinib combination with Anlotinib | Shanghai Zhongshan Hospital | NSCLC | 01/26 | 07/28 | | |
WUKONG-32, NCT06348927: Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC |
|
|
| Recruiting | 2 | 52 | RoW | sunvozertinib in combination with Anlotinib | Hunan Province Tumor Hospital | Non-Small Cell Lung Cancer | 10/25 | 04/27 | | |
| Recruiting | 2 | 100 | RoW | sunvozertinib in combination with Anlotinib | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 12/25 | 12/27 | | |
NUMER, NCT06563999: Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. |
|
|
| Recruiting | 2 | 120 | RoW | Sunvozertinib, DZD9008, Crizotinib, Xalkori, Pralsetinib, GAVRETO, Larotrectinib, VITRAKVI, Savolitinib, ORPATHYS, Pyrotinib, SHR1258, Dabrafenib+Trametinib, Glecirasib, JAB-21822, Ensartinib, X-396 | Sun Yat-sen University | Lung Cancer Stage III, Mutation | 11/27 | 11/29 | | |
ChiCTR2400084053: A phase II study of sunvozertinib combined with anlotinib hydrochloride in the treatment of advanced non-small cell lung cancer harboring EGFR non-classical mutations. |
|
|
| Recruiting | 2 | 40 | | Sunvozertinib combined with anlotinib hydrochloride; Sunvozertinib combined with anlotinib hydrochloride | Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences, No funding | Lung cancer | | | | |
2019-003126-25: A study to assess the Safety, Tolerability, Pharmacokinetics and Anti tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation Estudio para evaluar la seguridad, la tolerabilidad, la farmacocinética y la eficacia antitumoral de DZD9008 en pacientes con cáncer de pulmón no microcítico (CPNM) avanzado con mutación de EGFR o HER2 |
|
|
| Not yet recruiting | 1/2 | 356 | Europe | DZD9008, DZD9008, Tablet | Dizal (Jiangsu) Pharmaceutical Co., Ltd, DIZAL (JIANGSU) PHARMACEUTICAL CO.,LTD, Dizal (Jiangsu) Pharmaceutical Co., Ltd | Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico, Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico, Diseases [C] - Cancer [C04] | | | | |
WU-KONG1, NCT03974022: Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer with EGFR or HER2 Mutation |
|
|
| Active, not recruiting | 1/2 | 315 | Europe, Canada, Japan, US, RoW | Sunvozertinib, DZD9008 | Dizal Pharmaceuticals | Non-Small Cell Lung Cancer | 07/24 | 07/25 | | |
WU-KONG36, NCT06195189: Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II |
|
|
| Recruiting | 1/2 | 40 | RoW | Sunvozertinib, Chemotherapy | Sichuan University | Non Small Cell Lung Cancer | 12/25 | 02/26 | | |
ChiCTR2400080629: Sunvozertinib combined with chemotherapy for EGFRm + Locally Advanced or Metastasis NSCLC Patients After EGFR-TKI Treatment Failure:Phase I/II (WU-KONG36) |
|
|
| Not yet recruiting | 1/2 | 40 | | Sunvozertinib combined with chemotherapy(Pemetrexed +platinum) | West China Hospital,Sichuan University; West China Hospital,Sichuan University, Dizal (Jiangsu) Pharmaceutical | cancer | | | | |
| Completed | 1 | 15 | China | sunvozertinib (DZD9008) - Dizal Pharma | DiZhe (Jiangsu) Pharmaceutical Co., Ltd. | Advanced non-small cell lung cancer with EGFR or HER2 mutations | | | | |
NCT05418582: Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine |
|
|
| Completed | 1 | 40 | US | DZD9008 and intraconazole, DZD9008 and carbamazepine | Dizal Pharmaceuticals | Healthy Subjects | 06/22 | 12/22 | | |
NCT06084104: DZD9008 PK Study in Hepatic Impairment Subjects |
|
|
| Completed | 1 | 17 | US | DZD9008 | Dizal Pharmaceuticals, PPD Development, L.P. | Hepatic Impairment | 06/24 | 10/24 | | |
NCT05926180: Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19) |
|
|
| Completed | 1 | 25 | RoW | DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin), Inapplicable | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 05/24 | 09/24 | | |
WU-KONG15, NCT05559645: Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations |
|
|
| Recruiting | N/A | 180 | RoW | DZD9008 | Peking Union Medical College Hospital, Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Non Small Cell Lung Cancer | 12/25 | 06/26 | | |
| DZD3969 / AstraZeneca |
NCT04277468: Assessing an Oral SERD, DZD3969 in Patients With Advanced ER+HER2- Breast Cancer (MU-LAN1) |
|
|
| Not yet recruiting | 1/2 | 162 | NA | DZD3969 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Breast Neoplasms | 06/22 | 09/22 | | |
| DZD1516 / Dizal Pharma |
NCT04509596: DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer |
|
|
| Active, not recruiting | 1 | 23 | US, RoW | DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C | Dizal Pharmaceuticals | Breast Cancer Metastatic | 01/24 | 05/24 | | |
| DZD8586 / Dizal Pharma |
NCT06539195: DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) |
|
|
| Recruiting | 2 | 180 | RoW | DZD8586 | Dizal Pharmaceuticals | Diffuse Large B Cell Lymphoma | 10/27 | 04/28 | | |
NCT06539182: DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) |
|
|
| Recruiting | 2 | 155 | RoW | DZD8586 | Dizal Pharmaceuticals | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 09/27 | 03/28 | | |
| Recruiting | 1/2 | 386 | RoW | DZD8586 | Dizal Pharmaceuticals | Lymphoma, Non-Hodgkin | 04/27 | 10/27 | | |
| Recruiting | 1 | 230 | US, RoW | DZD8586 | Dizal Pharmaceuticals | Lymphoma, Non-Hodgkin | 04/27 | 10/27 | | |
